Peira, E.; Sapino, S.; Chirio, D.; Bucciol, F.; Turku, F.; Calcio Gaudino, E.; Cravotto, G.; Riganti, C.; Gallarate, M.
Formulation and Comparative Characterization of SLNs and NLCs for Targeted Co-Delivery of Paclitaxel and Hydroxytyrosol Carboxylic Acid Esters Against Triple-Negative Breast Cancer. Pharmaceutics 2025, 17, 1208.
https://doi.org/10.3390/pharmaceutics17091208
AMA Style
Peira E, Sapino S, Chirio D, Bucciol F, Turku F, Calcio Gaudino E, Cravotto G, Riganti C, Gallarate M.
Formulation and Comparative Characterization of SLNs and NLCs for Targeted Co-Delivery of Paclitaxel and Hydroxytyrosol Carboxylic Acid Esters Against Triple-Negative Breast Cancer. Pharmaceutics. 2025; 17(9):1208.
https://doi.org/10.3390/pharmaceutics17091208
Chicago/Turabian Style
Peira, Elena, Simona Sapino, Daniela Chirio, Fabio Bucciol, Flavia Turku, Emanuela Calcio Gaudino, Giancarlo Cravotto, Chiara Riganti, and Marina Gallarate.
2025. "Formulation and Comparative Characterization of SLNs and NLCs for Targeted Co-Delivery of Paclitaxel and Hydroxytyrosol Carboxylic Acid Esters Against Triple-Negative Breast Cancer" Pharmaceutics 17, no. 9: 1208.
https://doi.org/10.3390/pharmaceutics17091208
APA Style
Peira, E., Sapino, S., Chirio, D., Bucciol, F., Turku, F., Calcio Gaudino, E., Cravotto, G., Riganti, C., & Gallarate, M.
(2025). Formulation and Comparative Characterization of SLNs and NLCs for Targeted Co-Delivery of Paclitaxel and Hydroxytyrosol Carboxylic Acid Esters Against Triple-Negative Breast Cancer. Pharmaceutics, 17(9), 1208.
https://doi.org/10.3390/pharmaceutics17091208
